Subscribe to RSS
DOI: 10.4103/ijmpo.ijmpo_111_20
Breast Cancer Treatment during the COVID-19 Pandemic
COVID-19 pandemic has challenged the prioritization of various diseases in all healthcare systems for humanity across the globe, and cancer patients are not an exception. Approximately, 160,000 new cases and 80,000 deaths are attributed to breast cancer annually and it is the most common cancer in women in India.[1] In India, most of the patients with cancer need to travel a long distance to consult an oncologist and pursue cancer treatment. Further, such patients may be predisposed to COVID-19 infection during chemotherapy sessions in day-care centers. To reduce the infections among cancer patients and also to reduce the burden on existing infrastructure of healthcare, we formulated guidance.
Publication History
Received: 28 March 2020
Accepted: 11 April 2020
Article published online:
23 May 2021
© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Globocan 2018: India Factsheet. India against Cancer. 2018 http://cancerindia.org.in/globocan-2018-india-factsheet/ October Available from: [Last accessed on 2020 Apr 07]
- 2 Predict Breast. https://breast.predict.nhs.uk/tool Available from: [Last accessed on 2020 Mar 23]
- 3 Team TNCPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. CCDCW 2020; 2: 113-22
- 4 Liang W, Guan W, Chen R, Wang W, Li J, Xu K. et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol 2020; 21: 335-7
- 5 Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020; 21: e181
- 6 Earl HM, Hiller L, Vallier A-L, Loi S, McAdam K, Hughes-Davies L. et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. The Lancet 2019; 393: 2599-612
- 7 Diaz JH. Hypothesis: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med 2020; pii: taaa041
- 8 Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G. et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2020; pii S0735-1097 (20) 34637-4
- 9 http://Breast-Resource-During-COVID-19-3.30.20.pdf Available from: [Last accessed on 2020 Apr 07]
- 10 Wang SL, Fang H, Song YW, Wang WH, Hu C, Liu YP. et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: A randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2019; 20: 352-60
- 11 Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM. et al. Accelerated partial breast irradiation: Executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol 2017; 7: 73-9
- 12 http://Telemedicine.pdf Available from: [Last accessed on 2020 Apr 07]